FDA Committees To View OTCs
The US Food and Drug Administration Advisory Committees for nonprescription drugs and pulmonary drugs are to discuss antiasthma drugs at a joint meeting on November 14-15. The Nonprescription Drug Manufacturers Association says they will also discuss the use of antihistamines in treating the common cold, although it notes that this meeting has not been officially announced.
The agency's advisory committees for nonprescription drugs, dermatologicals and anti-infectives are also due to meet the next day (November 16), in a rescheduled session to discuss the potential for developing resistance to antibiotics with the use of topical erythromycin available over the counter.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Today's issue
Company Spotlight
Copyright © The Pharma Letter 2025 | Headless Content Management with Blaze